Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

PARIS, FRANCE, March 12^th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective April 1^st, 2025. She will serve on Ipsen’s Executive Leadership Team (ELT) and report directly to Chief Executive Officer David Loew. In this newly created role, she will lead Ipsen’s global neurotoxins franchise, overseeing strategy and execution across both therapeutic and aesthetic indications.

Over the last 30 years in the neurotoxins market, Ipsen has established itself as one of the leading players in neurosciences, successfully driving research, clinical development and growth based on significant manufacturing know-how and capacity.

"We are delighted to welcome Olivia to Ipsen’s Executive Leadership Team. With her deep expertise in neurotoxins, combined with her experience in global strategy and commercialization, she will be instrumental in further accelerating our growth and innovation in neurotoxins, both in the therapeutic and aesthetic space," said David Loew, CEO, Ipsen. “With a robust portfolio of products and an attractive pipeline including the potential break-through innovation of the recombinant Long-Acting Neuro-Toxine (LANT) program, it is the right time for us to create an integrated franchise. The long acting neurotoxin was uniquely designed to bind to the receptors used by the BoNT B and to deliver the active light chain of the BoNT A, demonstrating in preclinical studies a longer duration of action and less tissue spread compared to currently available BoNT As. We believe LANT AB has the potential ability to deliver better outcomes for patients with an increased duration of action, leading to a potential reduction in injection frequency and enhanced tolerability.”

Olivia brings over 20 years of global leadership experience in pharmaceuticals and medical aesthetics, with a strong track record in business transformation, market expansion, and product launches. Most recently, she was at Novartis, where she led the establishment of a new therapeutic area in Allergy & Immunology. Previously, she held senior leadership positions at Merz Aesthetics and Galderma, where she played a key role in expanding the global neurotoxins market.

"I am excited to join Ipsen at such an important time for its neurotoxins business. Ipsen has a strong foundation in innovation, and I look forward to working with the team to build on this success and drive further growth in this dynamic market,” said Olivia Brown.

This appointment reflects Ipsen’s continued investment in neurotoxin innovation, global expansion, and leadership in both therapeutic and aesthetic indications.

* botulinum toxin type B (BoNT-B)
** botulinum toxin type A (BoNT-A)

About Ipsen
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Ipsen contacts

Investors

Alina LEVCHUK | + 41 79 572 8712 | alina.levchuk@ipsen.com
Nicolas BOGLER | + 33 6 52 19 98 92 | nicolas.bogler@ipsen.com

Media

Sally BAIN | + 1 857 320 0517 | sally.bain@ipsen.com
Anne LIONTAS | + 33 7 67 34 72 96 | anne.liontas.ext@ipsen.com

Disclaimers and/or Forward-Looking Statements
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com.

Attachment